Can ENHANCE Diminish Vytorin? Schering, Merck Minimize Trial’s Importance

Schering-Plough and Merck are downplaying the significance of upcoming results from the ENHANCE trial comparing Vytorin (ezetimibe/simvastatin) to simvastatin alone in inhibiting atherosclerosis of the carotid artery

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet